Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.

ABSTRACT:

Aims/hypothesis

The long-term effects of successful immune therapies for treatment of type 1 diabetes have not been well studied. The Autoimmunity-Blocking Antibody for Tolerance (AbATE) trial evaluated teplizumab, an Fc receptor non-binding humanised anti-CD3 monoclonal antibody in individuals with new-onset type 1 diabetes, and ended in 2011. Clinical drug-treated responders showed an increased frequency of 'partially exhausted' CD8⁺ T cells. We studied the clinical, immunological and metabolic status of participants after an average follow-up of 7 years.

Methods

Participants with detectable C-peptide at year 2 of AbATE returned for follow-up. C-peptide responses were assessed by 4 h mixed-meal tolerance test. Autoantibodies and HbA_1c levels were meas

SUBMITTER: Perdigoto AL 

PROVIDER: S-EPMC6402971 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature